GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00343682 | Liver | NAFLD | protein-lipid complex remodeling | 12/1882 | 30/18723 | 1.58e-05 | 4.56e-04 | 12 |
GO:00343692 | Liver | NAFLD | plasma lipoprotein particle remodeling | 12/1882 | 30/18723 | 1.58e-05 | 4.56e-04 | 12 |
GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
GO:00343672 | Liver | NAFLD | protein-containing complex remodeling | 12/1882 | 32/18723 | 3.40e-05 | 8.80e-04 | 12 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:00066943 | Liver | NAFLD | steroid biosynthetic process | 34/1882 | 173/18723 | 1.01e-04 | 2.02e-03 | 34 |
GO:00097437 | Liver | NAFLD | response to carbohydrate | 45/1882 | 253/18723 | 1.07e-04 | 2.11e-03 | 45 |
GO:00650052 | Liver | NAFLD | protein-lipid complex assembly | 11/1882 | 31/18723 | 1.29e-04 | 2.47e-03 | 11 |
GO:00343772 | Liver | NAFLD | plasma lipoprotein particle assembly | 10/1882 | 27/18723 | 1.74e-04 | 3.08e-03 | 10 |
GO:1905952 | Liver | NAFLD | regulation of lipid localization | 34/1882 | 181/18723 | 2.51e-04 | 4.12e-03 | 34 |
GO:00464612 | Liver | NAFLD | neutral lipid catabolic process | 12/1882 | 39/18723 | 3.02e-04 | 4.75e-03 | 12 |
GO:00464642 | Liver | NAFLD | acylglycerol catabolic process | 12/1882 | 39/18723 | 3.02e-04 | 4.75e-03 | 12 |
GO:00343792 | Liver | NAFLD | very-low-density lipoprotein particle assembly | 6/1882 | 11/18723 | 3.03e-04 | 4.75e-03 | 6 |
GO:00192183 | Liver | NAFLD | regulation of steroid metabolic process | 22/1882 | 100/18723 | 3.22e-04 | 4.98e-03 | 22 |
GO:00468903 | Liver | NAFLD | regulation of lipid biosynthetic process | 32/1882 | 171/18723 | 4.03e-04 | 5.99e-03 | 32 |
GO:1905954 | Liver | NAFLD | positive regulation of lipid localization | 23/1882 | 110/18723 | 5.16e-04 | 7.15e-03 | 23 |
GO:0034374 | Liver | NAFLD | low-density lipoprotein particle remodeling | 7/1882 | 16/18723 | 5.17e-04 | 7.15e-03 | 7 |
GO:0019915 | Liver | NAFLD | lipid storage | 19/1882 | 87/18723 | 8.80e-04 | 1.07e-02 | 19 |
GO:0010883 | Liver | NAFLD | regulation of lipid storage | 14/1882 | 57/18723 | 1.24e-03 | 1.41e-02 | 14 |
GO:00512356 | Liver | NAFLD | maintenance of location | 50/1882 | 327/18723 | 1.75e-03 | 1.82e-02 | 50 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0541714 | Liver | NAFLD | Lipid and atherosclerosis | 42/1043 | 215/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 42 |
hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0541715 | Liver | NAFLD | Lipid and atherosclerosis | 42/1043 | 215/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 42 |
hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541722 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541732 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa0541712 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa04975 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
hsa0541713 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa049751 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
hsa0541710 | Stomach | SIM | Lipid and atherosclerosis | 34/465 | 215/8465 | 1.80e-08 | 4.20e-07 | 3.37e-07 | 34 |
hsa049752 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
hsa04979 | Stomach | SIM | Cholesterol metabolism | 8/465 | 51/8465 | 6.17e-03 | 3.83e-02 | 3.08e-02 | 8 |
hsa0541711 | Stomach | SIM | Lipid and atherosclerosis | 34/465 | 215/8465 | 1.80e-08 | 4.20e-07 | 3.37e-07 | 34 |
hsa049753 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
hsa049791 | Stomach | SIM | Cholesterol metabolism | 8/465 | 51/8465 | 6.17e-03 | 3.83e-02 | 3.08e-02 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APOB | SNV | Missense_Mutation | novel | c.8392G>C | p.Glu2798Gln | p.E2798Q | P04114 | protein_coding | tolerated(0.3) | benign(0.138) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
APOB | SNV | Missense_Mutation | novel | c.13546N>A | p.Glu4516Lys | p.E4516K | P04114 | protein_coding | tolerated(0.1) | possibly_damaging(0.485) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
APOB | SNV | Missense_Mutation | | c.7482N>G | p.Asn2494Lys | p.N2494K | P04114 | protein_coding | tolerated(0.35) | benign(0.031) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
APOB | SNV | Missense_Mutation | rs371177562 | c.12677C>T | p.Thr4226Met | p.T4226M | P04114 | protein_coding | deleterious(0.04) | benign(0) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
APOB | SNV | Missense_Mutation | | c.10418N>T | p.Ala3473Val | p.A3473V | P04114 | protein_coding | deleterious(0.05) | benign(0.047) | TCGA-A7-A3RF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
APOB | SNV | Missense_Mutation | | c.8477N>G | p.Glu2826Gly | p.E2826G | P04114 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
APOB | SNV | Missense_Mutation | | c.5615N>A | p.Ile1872Asn | p.I1872N | P04114 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-A8-A08O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | PD |
APOB | SNV | Missense_Mutation | | c.12526N>A | p.Val4176Ile | p.V4176I | P04114 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
APOB | SNV | Missense_Mutation | | c.2266N>T | p.Leu756Phe | p.L756F | P04114 | protein_coding | tolerated(0.72) | benign(0.001) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APOB | SNV | Missense_Mutation | | c.9739N>G | p.Gln3247Glu | p.Q3247E | P04114 | protein_coding | tolerated(0.12) | benign(0.127) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | ETHANOL | ALCOHOL | 8576634 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LOVASTATIN | LOVASTATIN | 2351867,7662319,1588827 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LIGNAN | | 15671223 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | TKM-APOB | | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | QUERCETIN | QUERCETIN | 16149735 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | lomitapide | LOMITAPIDE | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | EPIGALLOCATECHIN GALLATE | | 11936850 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PRAVASTATIN | PRAVASTATIN | 8312689 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | warfarin | WARFARIN | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | DEXAMETHASONE | DEXAMETHASONE | 7670964 |